+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery



Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery



Thrombosis Journal 13: 37



The aim of this study was to assess the safety and efficacy of switching therapy from low molecular weight heparin (LMWH; enoxaparin) to dabigatran for prevention of venous thromboembolic events (VTE) in patients undergoing elective total hip or knee replacement surgery (THR/TKR). This was a prospective, multicenter, open-label, single-arm, observational, study in patients undergoing THR or TKR who were to receive enoxaparin 40 mg for thromboprophylaxis. Enoxaparin was initiated before or after surgery according to local practice, and was switched to dabigatran 220 mg once daily at a time point chosen by the investigator. The coprimary endpoints were major bleeding events, and the composite of symptomatic VTE and all-cause mortality, from last use of enoxaparin to 24 h after last intake of dabigatran. Altogether, 168 (81 THR, 87 TKR) patients were enrolled, of whom 161 received both enoxaparin and dabigatran, 2 received dabigatran only and 5 received enoxaparin only. The median time of the first dabigatran tablet was 24.0 h after the last LMWH dosage and the median number of days on dabigatran treatment was 36 days. No symptomatic VTE or death occurred during the study. One major bleeding event was seen at the surgical site and required treatment cessation. Three minor bleeding events were observed. In the normal clinical setting, switching from LMWH to dabigatran in patients who had undergone THR and TKR was safe and effective in preventing VTE. The reported adverse events and serious adverse events were consistent with the known safety profile for dabigatran. Switching from a subcutaneous to an oral anticoagulant may offer greater convenience in the outpatient setting after discharge. ClinicalTrials.gov identifier NCT01153698.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058802704

Download citation: RISBibTeXText

PMID: 26612979

DOI: 10.1186/s12959-015-0066-9


Related references

C0190: Switching from Low Molecular Weight Heparin to Dabigatran in Patients Undergoing Elective Total Hip or Knee Replacement Surgery is Effective with a Good Safety Profile. Thrombosis Research 133: S39-S40, 2014

A clinical trial comparing the efficacy and safety of enoxaparin in low molecular weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective knee replacement surgery. Journal of General Internal Medicine 9(4 Suppl. 2): 36, 1994

A clinical trial comparing the efficacy and safety of enoxaparin a low molecular weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective knee replacement surgery. Blood 82(10 Suppl. 1): 410A, 1993

Low-Molecular-Weight Heparin Therapy for Patients Undergoing Total Knee Replacement Surgery: Cost and Outcomes. Hospital Pharmacy 38(9): 833-840, 2003

Changes of thrombelastography in patients undergoing elective primary total knee and total hip replacement with low molecular heparin prophylaxis. Journal of Orthopaedic Surgery and Research 9: 52, 2015

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Thrombosis Research 144: 158-164, 2017

Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thrombosis and Haemostasis 109(1): 154-163, 2013

Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. Thrombosis Research 143: 103-110, 2017

The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. Thrombosis Research 132(6): 685-691, 2014

A randomised controlled trial to evaluate the efficacy of a health maintenance clinic intervention for patients undergoing elective primary total hip and knee replacement surgery. International Journal of Orthopaedic and Trauma Nursing 17(4): 171-179, 2013

Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Journal of Bone and Joint Surgery. American Volume 76(11): 1752, 1994

Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thrombosis and Haemostasis 77(1): 32-38, 1997

Prevention of proximal deep vein thrombosis in patients undergoing total hip or knee replacement A double-blind, randomised trial comparing a low molecular weight heparin to unfractionated heparin The ECHOS Trial. Annals of Hematology 80(Suppl. 1): A24, 2001

Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiology and Drug Safety 25(11): 1245-1252, 2016

Enoxaparin a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Blood 84(10 Suppl. 1): 246A, 1994